PPBT

PURPLE BIOTECH LTD. PPBT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-26.39M

Quarter to Dec 31

Free cash flow

$-5.66M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$141.0K total
SmartHarvest Portfolios, LLC
$47.8K+57.0%
HRT FINANCIAL LP
$24.0KNew
CITADEL ADVISORS LLC
$22.1KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$21.6K-75.9%
Independent Advisor Alliance
$20.0KNew
SRS Capital Advisors, Inc.
$2.4KNew
RHUMBLINE ADVISERS
$1.4K+20.6%
UBS Group AG
$1.3K+658.6%
MORGAN STANLEY
$331-65.9%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$130.0%
IFG Advisory, LLC
$12New
SBI Securities Co., Ltd.
$5-90.3%
ROYAL BANK OF CANADA
$0+1180.0%
See all 13 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

PPBT key financials by period

Reported revenue, net income and operating margin by fiscal year, from PURPLE BIOTECH LTD.'s annual filings on SEC EDGAR.

PURPLE BIOTECH LTD. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2020$1.0M$28.0M—
FY 2019$1.0M$5.8M—
FY 2018$1.0M$5.2M—
FY 2017$100.0K$12.2M—
Source: PPBT filings on SEC EDGAR →

About PURPLE BIOTECH LTD. (PPBT): stock profile, AI score and financials

PURPLE BIOTECH LTD. (PPBT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PPBT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), PURPLE BIOTECH LTD. reports net income of $-26.4M, free cash flow of $-5.7M. Top institutional holders of PPBT by reported 13-F value include SmartHarvest Portfolios, HRT FINANCIAL, CITADEL ADVISORS, based on the most recent SEC filings. PPBT trades on the Nasdaq exchange and files with the SEC under CIK 1614744. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PPBT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PURPLE BIOTECH LTD. directly from SEC EDGAR.

SEC EDGAR: CIK 1614744 →